A non-invasive, blood-based biopsy for kidney cancer can tell doctors how a patient’s disease is responding to treatment.
Known as liquid biopsies, these blood tests could help physicians better treat their patients by allowing them to see which treatments are working in real time without the need for repeated, invasive biopsies of solid tumors.
A clinical study published May 26 in the Journal of Clinical Oncology and led by University of Wisconsin–Madison scientists followed more than 100 patients undergoing treatment for renal cell carcinoma. Researchers isolated and measured circulating tumor cells, which tumors release into the blood. These cells can act as a signal of disease burden in a patient.
Changes in both the number of circulating tumor cells and their molecular profiles were able to predict how long a patient would survive while undergoing either new immune system-based treatments or receiving more traditional kidney cancer drugs.
“Cancer is not a static disease. As the disease progresses, molecular characteristics change over time, and these changes are important to understand how the disease responds to treatment as well as how resistance develops,” says Matthew Bootsma, a researcher in the UW School of Medicine and Public Health and one of the lead authors of the report. “That makes it really important for a clinician to have real-time access to these metrics.”












